These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 16459016

  • 1. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.
    Perrin P.
    Eur Urol; 2006 Mar; 49(3):418-9. PubMed ID: 16459016
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H, Egawa S.
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
    [Abstract] [Full Text] [Related]

  • 5. The cautionary tale of PSA testing.
    Hoffman RM, Zeliadt SB.
    Arch Intern Med; 2010 Jul 26; 170(14):1262-3. PubMed ID: 20660847
    [No Abstract] [Full Text] [Related]

  • 6. Is an improved PSA screening test in sight?
    Savage L.
    J Natl Cancer Inst; 2007 Oct 17; 99(20):1503-4. PubMed ID: 17925529
    [No Abstract] [Full Text] [Related]

  • 7. PSA screening: the bottom line.
    Elhilali MM.
    CMAJ; 2000 Mar 21; 162(6):791-2. PubMed ID: 10750466
    [No Abstract] [Full Text] [Related]

  • 8. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
    D'Amico AV.
    J Clin Oncol; 2008 Feb 20; 26(6):823-4. PubMed ID: 18281649
    [No Abstract] [Full Text] [Related]

  • 9. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M, Tomioka S, Sasaki M, Shima T, Suzuki N, Murakami S, Nakatsu H, Shimazaki J.
    Jpn J Clin Oncol; 2009 Nov 20; 39(11):727-31. PubMed ID: 19674994
    [Abstract] [Full Text] [Related]

  • 10. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ, Parker A.
    J Urol; 2005 Sep 20; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [The PSA test does not hold for screening. Good--but not good enough].
    Holmström B, Johansson M, Bratt O, Stattin P.
    Lakartidningen; 2005 Sep 20; 107(7):436, 438-9. PubMed ID: 20384076
    [No Abstract] [Full Text] [Related]

  • 13. Prostate cancer detection: beware of the low PSA.
    Haas GP.
    Can J Urol; 2007 Jun 20; 14(3):3534. PubMed ID: 17594742
    [No Abstract] [Full Text] [Related]

  • 14. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence.
    Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM.
    J Natl Cancer Inst; 2007 Oct 17; 99(20):1510-5. PubMed ID: 17925534
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N, Fujimoto K, Yoshikawa M, Tanaka M, Hirao Y, Kondo H, Saito I.
    Hinyokika Kiyo; 2007 Jul 17; 53(7):459-65. PubMed ID: 17702178
    [Abstract] [Full Text] [Related]

  • 18. [The use of prostate specific antigen in prostate cancer--prediction for treatment failure].
    Egawa S.
    Nihon Rinsho; 2002 Dec 17; 60 Suppl 11():100-6. PubMed ID: 12599553
    [No Abstract] [Full Text] [Related]

  • 19. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Namba Y, Kishikawa H, Takahara S, Ichikawa Y.
    Prostate Cancer Prostatic Dis; 2008 Dec 17; 11(3):258-63. PubMed ID: 17876341
    [Abstract] [Full Text] [Related]

  • 20. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
    Ito K, Yamamoto T, Miyakubo M, Takechi H, Ohi M, Shibata Y, Suzuki K.
    J Urol; 2007 Oct 17; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.